Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the chemotherapy induced peripheral neuropathy treatment market?
The market for treatment of chemotherapy-induced peripheral neuropathy has seen a robust growth in the recent past. The market size, which is anticipated to be $1.66 billion in 2024, is predicted to rise to $1.78 billion by 2025, reflecting a compound annual growth rate (CAGR) of 7.1%. Contributing factors to the growth during the historical period include advancements in chemotherapy, wider scope of cancer treatments, lack of treatment alternatives, rising instances of cancer and advancements in neurological research.
What will be the chemotherapy induced peripheral neuropathy treatment market size in the future?
In the coming years, the market size for treatment of chemotherapy-related peripheral neuropathy is predicted to witness robust expansion. Anticipated to reach $2.5 billion by 2029, with an impressive compound annual growth rate (CAGR) of 8.9%, this growth is attributed to factors such as advancements in targeted therapies, the development of neuroprotective agents, integrated treatment approaches, patient-focused care models, and regulatory support. The forecast period will also see emerging trends such as innovative drug formulations, non-drug interventions, neuroplasticity-oriented therapies, comprehensive long-term survivor support, and cognitive behavioral therapies.
Get your chemotherapy induced peripheral neuropathy treatment market report here!
What main drivers are fueling expansion in the chemotherapy induced peripheral neuropathy treatment market?
The escalating occurrence of cancer is set to fuel the expansion of the market for treatment of chemotherapy-induced peripheral neuropathy. Cancer, typified by uncontrolled proliferation and dispersal of abnormal cells in the body, can lead to chemotherapy-induced peripheral neuropathy as a possible unintended outcome of specific chemotherapy medications. The expansion of the market for treatment of chemotherapy-induced peripheral neuropathy is tied to the increasing instances of cancer worldwide. For example, based on a report by the American Cancer Society, a voluntary health organization in the US focused on cancer eradication, it was found that there was a rise in the diagnosis of liver cancer in women from 12,660 in 2022 to 13,230 in 2023. Consequently, the rising frequency of cancer is steering the growth of the market for chemotherapy-induced peripheral neuropathy treatment.
What key areas define the segmentation of the global chemotherapy induced peripheral neuropathy treatment market?
The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented –
1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics
Subsegments:
1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine
2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine
4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10
5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp
Who are the dominant players expanding their reach in the chemotherapy induced peripheral neuropathy treatment market?
Major companies operating in the chemotherapy induced peripheral neuropathy treatment market include Hoffmann-La Roche Ltd., Midatech Pharma PLC, Novartis AG, Lee’s Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, Eurofins Advinus, WEX Pharmaceuticals Inc., Asahi Kasei Corporation, MediciNova Inc., Solasia Pharma K.K., ESTEVE, ChromaDex Inc., Apollo Endosurgery Inc., REGENACY PHARMACEUTICALS INC., Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., WinSanTor Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation
How are evolving market trends shaping chemotherapy induced peripheral neuropathy treatment Strategies?
The trend of product innovation is becoming increasingly prevalent in the chemotherapy-induced peripheral neuropathy treatment market. Key players in this industry are striving to create novel products to enhance their competitive edge and maintain their market position. For instance, in March 2023, AlgoTx, a firm in the clinical-stage sector that specializes in challenging pain control, announced that the FDA has given approval to their Investigational New Drug Application (IND) for their Phase 2 pioneer, ATX01. This ground-breaking treatment is designed for erythromelalgia patients. Concurrently, the first patients for the ATX01 for the Pain of Chemotherapy (ACT) study, pertaining to chemotherapy-induced peripheral neuropathy (CIPN), have been enlisted. Both programs have been granted fast-track designation by the FDA.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11967
Which regions are emerging as leaders in the chemotherapy induced peripheral neuropathy treatment market?
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2024. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
AgroScience Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/agroscience-global-market-report
Chitosan Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chitosan-global-market-report
Agricultural Implement Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/agricultural-implement-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
